Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
- Status
- WITHDRAWN
- Phase
- PHASE2
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
- Status
- COMPLETED
- Phase
- PHASE1
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
- Status
- COMPLETED
- Phase
- PHASE2
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Eribulin and Lenvatinib in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
- Status
- COMPLETED
- Phase
- NA
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
- Status
- COMPLETED
- Phase
- PHASE1
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
- Status
- COMPLETED
- Phase
- N/A
A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)
- Status
- COMPLETED
- Phase
- PHASE1